SC
BMRN icon

Shay Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shay Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,000
Closed -$437K – 292
2024
Q1 		$437K Buy
+5,000
New +$448K 0.07% 198
2022
Q1 		– Sell
-16,000
Closed -$1.41M – 519
2021
Q4 		$1.41M Buy
+16,000
New +$1.32M 0.23% 77

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Shay Capital's BMRN Position: Q1 2021 in Review

Shay Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 4,000 shares — an estimated $351K sold.

Shay Capital first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $351K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Shay Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Shay Capital sold 4,000 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $351K.
  • Shay Capital first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Shay Capital's BioMarin Pharmaceuticals position peaked at $351K in Q4 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Shay Capital's 13F filing for Q1 2021, filed 13 Aug 2021.